Experienced research scientist providing value for patent prosecution and counseling
As a patent agent, Kate Prybylowski, PhD, focuses her practice on US and foreign patent prosecution in the life sciences area. Kate also assists teams on due diligence investigations and other counseling matters by evaluating the underlying technology of inventions. Kate also has experience preparing IPR petitions and expert declarations.
Kate has extensive pharmaceutical experience across a range of therapeutic areas, including neuroscience, immunology, and fibrosis. She brings substantial technical experience, as well as a background in medical writing.
Prior to working with McNeill Baur PLLC, Kate worked as a Medical Director at a medical communications firm developing launch training materials for therapies for diseases including type 2 diabetes mellitus, Parkinson’s disease, and chronic lymphocytic leukemia. She has received certification in medical writing from the American Medical Writers Association.
Kate previously worked as a Senior Research Investigator at Sanofi in the central nervous system and fibrosis units focusing on development of therapies for multiple sclerosis, neuropathic pain, and lung fibrosis. She has extensive experience in assay development with expertise ranging from high-throughput screening technologies to primary cell culture assays. Kate’s areas of expertise include calcium-based assays, gene expression arrays, and high-throughput imaging techniques. She has developed assays to drive optimization of small molecules, botanical extracts, and natural products.
Prior to Sanofi, Kate worked at the National Institutes of Health as a PRAT fellow and also received a National Research Council fellowship from the National Academies of Sciences. At the NIH, her work focused on synaptic transmission with technical expertise in patch-clamp electrophysiology, immunohistochemistry, and molecular biology techniques.
Kate’s doctoral work was at Georgetown University in the Department of Pharmacology, where she studied the role of alternative splicing in regulating the function of NMDA receptors in the brain and spinal cord.
“The synaptic localization of NR2B-containing NMDA receptors is controlled by interactions with PDZ proteins and AP-2,” Neuron 47(6):845-57 (2005) (coauthor).
“N-Methyl-D-aspartate receptors: subunit assembly and trafficking to the synapse,” J Biol Chem. 279(11):9673-6 (2004) (coauthor).
“Relationship between availability of NMDA receptor subunits and their expression at the synapse,” J Neurosci. 22(20):8902-10 (2002) (coauthor).
“Expression of splice variants of the NR1 subunit of the NMDA receptor in normal and injured rat spinal cord,” J Neurochem. 76(3): 797-805 (2001) (coauthor).
“Developmental differences in alternative splicing of the NR1 protein in rat cortex and cerebellum,” Brain Res Dev Brain Res. 123(2): 143-150 (2000) (coauthor).
“Increased exon 5 expression alters extrasynaptic receptors in cerebellar neurons,” , J Neurochem. 75(3): 1140-6 (2000) (coauthor).